The entire cell therapy field is experiencing a shift towards allogeneic platforms as the potential to achieve a truly off-the-shelf, universal, and efficacious cell therapy offers great advantages such as reduced cost, production and patient accessibility compared to its autologous counterparts.
Across a jam-packed agenda consisting of 60+ hours of content, 3 in-depth tracks, 1 Investor & Business Development Focus Day, 1 Beyond Oncology Bootcamp Day and more; our 50+ expert speakers will lead you and your peers in discussions that will help to transform universal cell therapies for patients across the globe.
Learn more here: https://ter.li/aetc0d